Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 733

1.

[Effects of patient-controlled intravenous analgesia using hydromorphone supplement with dexmedetomidine on patients undergoing transcatheter arterial chemoembolization].

Wang HW, Li LL, Li ZS, Cheng LN.

Zhonghua Zhong Liu Za Zhi. 2018 Aug 23;40(8):626-630. doi: 10.3760/cma.j.issn.0253-3766.2018.08.012. Chinese.

PMID:
30139035
2.

Emergency Department Use of Intravenous Prochlorperazine for Acute Migraine.

Cook C, Newberry B.

Adv Emerg Nurs J. 2018 Jul/Sep;40(3):148-154. doi: 10.1097/TME.0000000000000203.

PMID:
30059368
3.

Parenteral Opioid Shortage - Treating Pain during the Opioid-Overdose Epidemic.

Bruera E.

N Engl J Med. 2018 Aug 16;379(7):601-603. doi: 10.1056/NEJMp1807117. Epub 2018 Jul 18. No abstract available.

4.

Patient Preference for Pain Medication in the Emergency Department Is Associated with Non-fatal Overdose History.

Whiteside LK, Goldstick J, Dora-Laskey A, Thomas L, Walton M, Cunningham R, Bohnert ASB.

West J Emerg Med. 2018 Jul;19(4):722-730. doi: 10.5811/westjem.2018.4.37019. Epub 2018 Jun 11.

6.

A double-blind, randomized comparative study to investigate the morphine to hydromorphone conversion ratio in Japanese cancer patients.

Inoue S, Saito Y, Tsuneto S, Aruga E, Ogata T, Uemori M.

Jpn J Clin Oncol. 2018 May 1;48(5):442-449. doi: 10.1093/jjco/hyy046.

7.

Hydromorphone use for acute pain: Misconceptions, controversies, and risks.

Mazer-Amirshahi M, Motov S, Nelson LS.

J Opioid Manag. 2018 Jan/Feb;14(1):61-71. doi: 10.5055/jom.2018.0430. Review.

PMID:
29508897
8.

Fatal Sickling Triggered by Massive Foreign Particle Embolism: A Case Report of Unrecognized Indwelling Venous Catheter Drug Abuse in Sickle Cell Disease.

Febres-Aldana CA, Hernandez Howard L.

Am J Forensic Med Pathol. 2018 Jun;39(2):152-156. doi: 10.1097/PAF.0000000000000378.

PMID:
29351102
9.

[A concentration-response observation of hydromorphone combined with ropivacaine in labor analgesia].

Lu YY, Huang H, Mao WL, Liu RH, Hu MJ, Shao LX, Hu MP, Li J.

Zhonghua Yi Xue Za Zhi. 2017 Nov 14;97(42):3297-3300. doi: 10.3760/cma.j.issn.0376-2491.2017.42.005. Chinese.

PMID:
29141373
10.

Randomized study of IV prochlorperazine plus diphenhydramine vs IV hydromorphone for migraine.

Friedman BW, Irizarry E, Solorzano C, Latev A, Rosa K, Zias E, Vinson DR, Bijur PE, Gallagher EJ.

Neurology. 2017 Nov 14;89(20):2075-2082. doi: 10.1212/WNL.0000000000004642. Epub 2017 Oct 18.

PMID:
29046364
11.

Identification of Circulating miRNAs Differentially Regulated by Opioid Treatment.

Toyama K, Kiyosawa N, Watanabe K, Ishizuka H.

Int J Mol Sci. 2017 Sep 16;18(9). pii: E1991. doi: 10.3390/ijms18091991.

12.

The Conversion Ratio From Intravenous Hydromorphone to Oral Opioids in Cancer Patients.

Reddy A, Vidal M, Stephen S, Baumgartner K, Dost S, Nguyen A, Heung Y, Kwan S, Wong A, Pangemanan I, Azhar A, Tayjasanant S, Rodriguez E, Waletich J, Lim KH, Wu J, Liu D, Williams J, Yennurajalingam S, Bruera E.

J Pain Symptom Manage. 2017 Sep;54(3):280-288. doi: 10.1016/j.jpainsymman.2017.07.001. Epub 2017 Jul 13.

PMID:
28711751
13.

Intravenous vs Oral Acetaminophen as an Adjunct to Multimodal Analgesia After Total Knee Arthroplasty: A Prospective, Randomized, Double-Blind Clinical Trial.

O'Neal JB, Freiberg AA, Yelle MD, Jiang Y, Zhang C, Gu Y, Kong X, Jian W, O'Neal WT, Wang J.

J Arthroplasty. 2017 Oct;32(10):3029-3033. doi: 10.1016/j.arth.2017.05.019. Epub 2017 May 18.

14.

Opioids for cancer pain - an overview of Cochrane reviews.

Wiffen PJ, Wee B, Derry S, Bell RF, Moore RA.

Cochrane Database Syst Rev. 2017 Jul 6;7:CD012592. doi: 10.1002/14651858.CD012592.pub2. Review.

PMID:
28683172
15.

Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.

Walsh SL, Comer SD, Lofwall MR, Vince B, Levy-Cooperman N, Kelsh D, Coe MA, Jones JD, Nuzzo PA, Tiberg F, Sheldon B, Kim S.

JAMA Psychiatry. 2017 Sep 1;74(9):894-902. doi: 10.1001/jamapsychiatry.2017.1874.

16.

A Multisite Retrospective Study Evaluating the Implementation of the Pasero Opioid-Induced Sedation Scale (POSS) and Its Effect on Patient Safety Outcomes.

Davis C, Geik C, Arthur K, Fuller J, Johnston E, Levitt F, Leung E, McCart G, McMichael D, Painter J, Staublin T, Walroth T.

Pain Manag Nurs. 2017 Aug;18(4):193-201. doi: 10.1016/j.pmn.2017.03.006. Epub 2017 Jun 9.

PMID:
28606595
17.

Challenging equipotency calculation for hydromorphone after long-term intravenous application.

Luchting B, Rachinger-Adam B, Hulde N, Heyn J, Azad SC.

Ann Palliat Med. 2017 Aug;6(Suppl 1):S90-S94. doi: 10.21037/apm.2017.03.01. Epub 2017 Mar 16.

18.

Men's and women's response to treatment and perceptions of outcomes in a randomized controlled trial of injectable opioid assisted treatment for severe opioid use disorder.

Palis H, Marchand K, Guh D, Brissette S, Lock K, MacDonald S, Harrison S, Anis AH, Krausz M, Marsh DC, Schechter MT, Oviedo-Joekes E.

Subst Abuse Treat Prev Policy. 2017 May 19;12(1):25. doi: 10.1186/s13011-017-0110-9.

19.

Safety profile of injectable hydromorphone and diacetylmorphine for long-term severe opioid use disorder.

Oviedo-Joekes E, Brissette S, MacDonald S, Guh D, Marchand K, Jutha S, Harrison S, Janmohamed A, Zhang DZ, Anis AH, Krausz M, Marsh DC, Schechter MT.

Drug Alcohol Depend. 2017 Jul 1;176:55-62. doi: 10.1016/j.drugalcdep.2017.02.021. Epub 2017 May 10.

PMID:
28521199
20.

Predictors of Response in Emergency Department Patients Receiving Intravenous Opioids for Severe Pain.

Radcliff JA, Rafeq RM, Bowen JF, Pontiggia L, Sen S.

Pharmacotherapy. 2017 Jul;37(7):799-805. doi: 10.1002/phar.1949.

PMID:
28500651

Supplemental Content

Loading ...
Support Center